Forward Pharma A/S (FWPAY)
| Market Cap | 19.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.89M |
| Shares Out | n/a |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 2.15 |
| Day's Range | n/a |
| 52-Week Range | 1.43 - 3.14 |
| Beta | 1.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About FWPAY
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark. [Read more]
Financial Performance
Financial StatementsNews
Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq St...
Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Paten...
Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated...
Why is Forward Pharma Stock Plunging During Premarket Tuesday?
The stock price of Forward Pharma A/S (NASDAQ: FWP) fell by almost 20% during the premarket. Investors are responding negatively to the Technical Board of Appeal (TBA) of the European Patent Office (...
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the Europe...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated...
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread...
A Trio of Stock Picks for the Short-Term Investor
There are investors who purchase shares of stocks that are trading below their liquidation value in the belief that they can make huge gains out of their investments after the market has reassessed th...
Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares
COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of...
Forward Pharma to Participate in the Fall Investor Summit in New York
COPENHAGEN, Denmark, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Chief Executive Officer, Dr. Claus Bo Svendsen, will participate in the F...